BACKGROUND: Patient-reportedoutcomes (PROs) that assess health-related quality of life (HRQoL) are increasingly important components of cancer care and research that are infrequently used in sub-Saharan Africa (SSA). METHODS: We administered the Chichewa Pediatric Patient-Reported Outcome Measurement Information System Pediatric (PROMIS)-25 at diagnosis, active treatment, and follow-up among pediatric lymphoma patients in Lilongwe, Malawi. Mean scores were calculated for the six PROMIS-25 HRQoL domains (Mobility, Anxiety, Depressive Symptoms, Fatigue, Peer Relationships, Pain Interference). Differences in HRQoL throughout treatment were compared using the minimally important difference (MID) and an ANOVA analysis. Kaplan-Meier survival estimates and Cox hazard ratios for mortality are reported. RESULTS: Seventy-five children completed PROMIS-25 surveys at diagnosis, 35 (47%) during active treatment, and 24 (32%) at follow-up. The majority of patients died (n = 37, 49%) or were lost to follow-up (n = 6, 8%). Most (n = 51, 68%) were male, median age was 10 (interquartile range [IQR] 8-12), 48/73 (66%) presented with advanced stage III/IV, 61 (81%) were diagnosed with Burkitt lymphoma and 14 (19%) Hodgkin lymphoma. At diagnosis, HRQoL was poor across all domains, except for Peer Relationships. Improvements in HRQoL during active treatment and follow-up exceeded the MID. On exploratory analysis, fair-poor PROMIS Mobility <40 and severe Pain Intensity = 10 at diagnosis were associated with increased mortality risk and worse survival, but were not statistically significant. CONCLUSIONS: Pediatric lymphoma patients in Malawi present with poor HRQoL that improves throughout treatment and survivorship. Baseline PROMIS scores may provide important prognostic information. PROs offer an opportunity to include patient voices and prioritize holistic patient-centered care in low-resource settings.
BACKGROUND: Patient-reportedoutcomes (PROs) that assess health-related quality of life (HRQoL) are increasingly important components of cancer care and research that are infrequently used in sub-Saharan Africa (SSA). METHODS: We administered the Chichewa Pediatric Patient-Reported Outcome Measurement Information System Pediatric (PROMIS)-25 at diagnosis, active treatment, and follow-up among pediatric lymphoma patients in Lilongwe, Malawi. Mean scores were calculated for the six PROMIS-25 HRQoL domains (Mobility, Anxiety, Depressive Symptoms, Fatigue, Peer Relationships, Pain Interference). Differences in HRQoL throughout treatment were compared using the minimally important difference (MID) and an ANOVA analysis. Kaplan-Meier survival estimates and Cox hazard ratios for mortality are reported. RESULTS: Seventy-five children completed PROMIS-25 surveys at diagnosis, 35 (47%) during active treatment, and 24 (32%) at follow-up. The majority of patients died (n = 37, 49%) or were lost to follow-up (n = 6, 8%). Most (n = 51, 68%) were male, median age was 10 (interquartile range [IQR] 8-12), 48/73 (66%) presented with advanced stage III/IV, 61 (81%) were diagnosed with Burkitt lymphoma and 14 (19%) Hodgkin lymphoma. At diagnosis, HRQoL was poor across all domains, except for Peer Relationships. Improvements in HRQoL during active treatment and follow-up exceeded the MID. On exploratory analysis, fair-poor PROMIS Mobility <40 and severe Pain Intensity = 10 at diagnosis were associated with increased mortality risk and worse survival, but were not statistically significant. CONCLUSIONS: Pediatric lymphoma patients in Malawi present with poor HRQoL that improves throughout treatment and survivorship. Baseline PROMIS scores may provide important prognostic information. PROs offer an opportunity to include patient voices and prioritize holistic patient-centered care in low-resource settings.
Authors: Christopher C Stanley; Kate D Westmoreland; Salama Itimu; Ande Salima; Toon van der Gronde; Peter Wasswa; Idah Mtete; Mercy Butia; Nader K El-Mallawany; Satish Gopal Journal: Pediatr Blood Cancer Date: 2016-11-28 Impact factor: 3.167
Authors: Felicia Marie Knaul; Paul E Farmer; Eric L Krakauer; Liliana De Lima; Afsan Bhadelia; Xiaoxiao Jiang Kwete; Héctor Arreola-Ornelas; Octavio Gómez-Dantés; Natalia M Rodriguez; George A O Alleyne; Stephen R Connor; David J Hunter; Diederik Lohman; Lukas Radbruch; María Del Rocío Sáenz Madrigal; Rifat Atun; Kathleen M Foley; Julio Frenk; Dean T Jamison; M R Rajagopal Journal: Lancet Date: 2017-10-12 Impact factor: 79.321
Authors: Pamela S Hinds; Suzanne L Nuss; Kathleen S Ruccione; Janice S Withycombe; Shana Jacobs; Holly DeLuca; Charisse Faulkner; Yang Liu; Yao I Cheng; Heather E Gross; Jichuan Wang; Darren A DeWalt Journal: Pediatr Blood Cancer Date: 2012-07-24 Impact factor: 3.167
Authors: James W Varni; David Thissen; Brian D Stucky; Yang Liu; Brooke Magnus; Hally Quinn; Debra E Irwin; Esi Morgan DeWitt; Jin-Shei Lai; Dagmar Amtmann; Heather E Gross; Darren A DeWalt Journal: Qual Life Res Date: 2013-06-06 Impact factor: 4.147
Authors: James W Varni; David Thissen; Brian D Stucky; Yang Liu; Hally Gorder; Debra E Irwin; Esi Morgan DeWitt; Jin-Shei Lai; Dagmar Amtmann; Darren A DeWalt Journal: Qual Life Res Date: 2011-10-05 Impact factor: 4.147
Authors: Darren A DeWalt; Heather E Gross; Debbie S Gipson; David T Selewski; Esi Morgan DeWitt; Carlton D Dampier; Pamela S Hinds; I-Chan Huang; David Thissen; James W Varni Journal: Qual Life Res Date: 2015-02-26 Impact factor: 4.147
Authors: Scott C Howard; Alia Zaidi; Xueyuan Cao; Olivier Weil; Pierre Bey; Catherine Patte; Angelica Samudio; Laurie Haddad; Catherine G Lam; Claude Moreira; Augusto Pereira; Mhamed Harif; Laila Hessissen; Salma Choudhury; Ligia Fu; Miguela A Caniza; Julius Lecciones; Fousseyni Traore; Raul C Ribeiro; Anne Gagnepain-Lacheteau Journal: Lancet Oncol Date: 2018-05 Impact factor: 41.316
Authors: Bryce B Reeve; Lloyd J Edwards; Byron C Jaeger; Pamela S Hinds; Carlton Dampier; Debbie S Gipson; David T Selewski; Jonathan P Troost; David Thissen; Vaughn Barry; Heather E Gross; Darren A DeWalt Journal: Qual Life Res Date: 2017-09-07 Impact factor: 4.147
Authors: Anjan K Banerjee; Sally Okun; I Ralph Edwards; Paul Wicks; Meredith Y Smith; Stephen J Mayall; Bruno Flamion; Charles Cleeland; Ethan Basch Journal: Drug Saf Date: 2013-12 Impact factor: 5.606